|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Pathophysiology/Complications |
Effect of Glucagon-Like Peptide 1 (7-36 Amide) on Insulin-Mediated Glucose Uptake in Patients With Type 1 Diabetes
1 Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
2 Departement of Physiology, University of British Columbia, Vancouver, British Columbia, Canada
3 Laboratory of Molecular Endocrinology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts
4 Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
5 Department of Drug Development, Restoragen, Inc., Lincoln, Nebraska
6 National Institute on Aging, National Institutes of Health, Baltimore, Maryland
OBJECTIVE—To examine the insulinomimetic insulin-independent effects of glucagon-like peptide (GLP)-1 on glucose uptake in type 1 diabetic patients.
RESEARCH DESIGN AND METHODS—We used the hyperinsulinemic-euglycemic clamp (480 pmol · m-2 · min-1) in paired randomized studies of six women and five men with type 1 diabetes. In the course of one of the paired studies, the subjects also received GLP-1 at a dose of 1.5 pmol · kg-1 · min-1. The patients were 41 ± 3 years old with a BMI of 25 ± 1 kg/m2. The mean duration of diabetes was 23 ± 3 years.
RESULTS—Plasma glucose was allowed to fall from a fasting level of 
11 mmol/l to 5.3 mmol/l in each study and thereafter was held stable at that level. Plasma insulin levels during both studies were 900 pmol/l. Plasma C-peptide levels did not change during the studies. In the GLP-1 study, plasma total GLP-1 levels were elevated from the fasting level of 31 ± 3 to 150 ± 17 pmol/l. Plasma glucagon levels fell from the fasting levels of 14 pmol/l to 9 pmol/l during both paired studies. Hepatic glucose production was suppressed during the glucose clamps in all studies. Glucose uptake was not different between the two studies (40 µmol · kg-1 · min-1).
CONCLUSIONS—GLP-1 does not augment insulin-mediated glucose uptake in lean type 1 diabetic patients.
Abbreviations: GLP, glucagon-like peptide • HGP, hepatic glucose production • rGLP-1, recombinant GLP-1(7-36) amide
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gromada, I. Franklin, and C. B. Wollheim {alpha}-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains Endocr. Rev., February 1, 2007; 28(1): 84 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Estrada-Smith, A. R. Collins, X. Wang, C. Crockett, L. Castellani, A. J. Lusis, and R. C. Davis Impact of Chromosome 2 Obesity Loci on Cardiovascular Complications of Insulin Resistance in LDL Receptor-Deficient C57BL/6 Mice. Diabetes, August 1, 2006; 55(8): 2265 - 2271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Franklin, J. Gromada, A. Gjinovci, S. Theander, and C. B. Wollheim {beta}-Cell Secretory Products Activate {alpha}-Cell ATP-Dependent Potassium Channels to Inhibit Glucagon Release Diabetes, June 1, 2005; 54(6): 1808 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dupre, M. T. Behme, and T. J. McDonald Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3469 - 3473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Meneilly, N. Greig, H. Tildesley, J. F. Habener, J. M. Egan, and D. Elahi Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2835 - 2841. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |